We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Appili Therapeutics Inc | TSX:APLI | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.035 | 0.035 | 0.04 | 0.04 | 0.035 | 0.04 | 151,001 | 20:31:20 |
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today.
Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the Company, including the election of the following directors for the ensuing year: Ian Mortimer, Brian Bloom, Juergen Froehlich, Theresa Matkovits, Rochelle Stenzler and Armand Balboni.
Voting results for each director are summarized below:
Name of Nominee
Percentage of Votes For
Percentage of Votes Against
Percentage of Votes Withheld
Ian Mortimer
19,490,794 (98.42%)
307,825 (1.55%)
5,300 (0.03%)
Brian Bloom
16,812,009 (84.89%)
2,985,610 (15.08%)
6,300 (0.03%)
Juergen Froehlich
16,808,009 (84.87%)
2,989,610 (15.10%)
6,300 (0.03%)
Theresa Matkovits
19,489,794 (98.41%)
307,825 (1.55%)
6,300 (0.03%)
Rochelle Stenzler
19,490,794 (98.42%)
307,825 (1.55%)
5,300 (0.03%)
Armand Balboni
16,808,009 (84.87%)
2,989,610 (15.10%)
6,300 (0.03%)
In addition to the election of the directors of the Company as noted above, the Shareholders:
The Company has filed a report of the voting results on all resolutions voted on the Meeting on the Company’s SEDAR profile at www.sedar.com
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including, a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic product for the treatment of a disfiguring disease, a broad-spectrum antifungal, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005885/en/
Media Contact: Danielle Raabe/APCO Worldwide T: 1-646-717-9915 E: DRaabe@apcoworldwide.com
Investor Relations Contact: Armand Balboni, CEO Appili Therapeutics Info@AppiliTherapeutics.com
1 Year Appili Therapeutics Chart |
1 Month Appili Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions